Edition:
India

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

36.55USD
17 Nov 2017
Change (% chg)

$-0.20 (-0.54%)
Prev Close
$36.75
Open
$36.55
Day's High
$37.00
Day's Low
$36.00
Volume
100,922
Avg. Vol
276,167
52-wk High
$42.60
52-wk Low
$7.70

Chart for

About

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008,... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,207.95
Shares Outstanding(Mil.): 31.54
Dividend: --
Yield (%): --

Financials

BRIEF-Zogenix posts Q3 loss of $1.68 per share

* Zogenix provides corporate update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Zogenix announces closing of public offering of common stock

* Zogenix announces closing of public offering of common stock, including full exercise of underwriters’ option to purchase additional shares Source text for Eikon: Further company coverage:

06 Oct 2017

BRIEF-Zogenix files for potential mixed shelf filing; size not disclosed - SEC filing‍​

* Files for potential mixed shelf filing; size not disclosed - SEC filing‍​ Source text : (http://bit.ly/2xOgvG9) Further company coverage:

02 Oct 2017

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

29 Sep 2017

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

29 Sep 2017

BRIEF-Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome

* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome

29 Sep 2017

Zogenix epilepsy drug meets main goal in late-stage trial

Sept 29 Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.

29 Sep 2017

BRIEF-Zogenix Q2 loss per share $0.93

* Zogenix provides corporate update and reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

03 Aug 2017

Earnings vs. Estimates